Showing results (1131-1140 of 1,153) with videos related to
Sort By:
Pageof 116
The Lancet. Haematology|March 1, 2023
Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin LymphomaAuke Beishuizen, Karin Mellgren, Mara Andrés, et al.Nature Communications|September 1, 2021
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphomaFabian Frontzek, Annette M Staiger, Myroslav Zapukhlyak, et al.Hematological Oncology|February 19, 2020
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trialChristine Schmitz, Jan Rekowski, Stefan P Müller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2018
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III TrialUlrich Dührsen, Stefan Müller, Bernd Hertenstein, et al.Blood|April 3, 2025
Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphomaAdrian Gottschlich, Ruth Grünmeier, Gordon Victor Hoffmann, et al.Proceedings of the National Academy of Sciences of the United States of America|October 23, 2013
Landscape of somatic mutations and clonal evolution in mantle cell lymphomaSílvia Beà, Rafael Valdés-Mas, Alba Navarro, et al.Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.Vaccines|July 27, 2022
Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel DiseasesKeren Masha Rabinowitz, Michal Navon, Hadar Edelman-Klapper, et al.Haematologica|April 16, 2026
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL studyMarie José Kersten, Martin Dreyling, Kim M Linton, et al.Annals of Hematology|January 6, 2019
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trialAndreas Hüttmann, Jan Rekowski, Stefan P Müller, et al.Pageof 116